Clarus Therapeutics (CRXTQ) News Today $0.0014 +0.00 (+40.00%) (As of 02/28/2023) Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Clarus Stock (NASDAQ:CLAR), Analyst Ratings, Price Targets, PredictionsJanuary 5, 2024 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Earnings Estimates, EPS, and RevenueOctober 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Analyst Ratings, Price Targets, PredictionsOctober 12, 2022 | benzinga.comClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeSeptember 5, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)July 28, 2022 | finance.yahoo.comClarus Therapeutics Holdings Inc.July 20, 2022 | wsj.comClarus Therapeutics Holdings, Inc. (CRXT)July 12, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingJune 9, 2022 | finance.yahoo.comClarus' oral testosterone product Jatenzo gets patent nodMay 18, 2022 | seekingalpha.comClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)May 18, 2022 | finance.yahoo.comClarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | seekingalpha.comClarus Therapeutics Misses Q1 EPS by 21cMay 16, 2022 | investing.comClarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsMay 16, 2022 | finance.yahoo.comClarus Therapeutics Q1 2022 Earnings PreviewMay 13, 2022 | seekingalpha.comClarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsMay 12, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisMay 10, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual MeetingMay 9, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)April 28, 2022 | finance.yahoo.comClarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public OfferingApril 27, 2022 | finance.yahoo.comWhy Clarus Therapeutics Shares Are Getting HammeredApril 25, 2022 | uk.investing.comYou Ask, We Analyze: What To Watch For In Clarus Therapeutics Stock Following Last Week's SurgeApril 25, 2022 | msn.comClarus Therapeutics nosedives on pricing upsized $30M stock and warrants offeringApril 25, 2022 | seekingalpha.comClarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public OfferingApril 25, 2022 | apnews.comClarus Therapeutics plunges 22% on equity offeringApril 25, 2022 | seekingalpha.comPre-market Movers: SCYX, DAIO, OMEX, CRSR, GPS…April 22, 2022 | nasdaq.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual MeetingApril 19, 2022 | finance.yahoo.comBioMed Momentum: VERU, NMLSF, PHRX, CRXT; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and AutismApril 14, 2022 | finance.yahoo.comClarus Therapeutics Tops Q4 EPS by 49cMarch 30, 2022 | uk.investing.comClarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating ResultsMarch 30, 2022 | morningstar.comClarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating ResultsMarch 29, 2022 | finance.yahoo.comDLNG, MULN and OCFT among mid-day moversMarch 27, 2022 | seekingalpha.comClarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney DiseaseMarch 16, 2022 | finance.yahoo.comClarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare ConferenceMarch 10, 2022 | finance.yahoo.comClarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to PatientsFebruary 24, 2022 | finance.yahoo.comAntares resubmitted NDA for testosterone replacement therapy Tlando accepted by FDAFebruary 3, 2022 | seekingalpha.comLipocine announces FDA accepted the marketing application for TlandoFebruary 3, 2022 | seekingalpha.comClarus Therapeutics Expects To Initiate In H2 2022, Phase 2 Trial To Provide Once Daily Oral Testosterone Undecanoate To Treat Male HypogonadismJanuary 20, 2022 | benzinga.comClarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development OfficerJanuary 18, 2022 | finance.yahoo.comClarus Therapeutics Holdings Inc Shares Close the Week 31.7% Lower - Weekly WrapJanuary 10, 2022 | nasdaq.comClarus Therapeutics Holdings Inc Shares Near 52-Week Low - Market MoverJanuary 9, 2022 | nasdaq.comClarus Therapeutics Holdings Inc Shares Fall 10.5% Below Previous 52-Week Low - Market MoverJanuary 7, 2022 | nasdaq.comClarus Therapeutics Holdings Inc Shares Close the Day 10.5% Lower - Daily WrapJanuary 7, 2022 | nasdaq.comClarus Therapeutics Holdings Inc (CRXT)January 5, 2022 | investing.comClarus Therapeutics Announces Closing of Approximately $15 Million Private PlacementDecember 7, 2021 | finance.yahoo.comClarus Therapeutics Announces $15 Million Private PlacementDecember 3, 2021 | finance.yahoo.comThinking about buying stock in Cumberland Pharmaceuticals, AT&T, Clarus Therapeutics, RLX Technology, or Norwegian Cruise Line?December 1, 2021 | benzinga.comClarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)November 30, 2021 | finance.yahoo.comTrading was temporarily halted for "CRXT" at 11:11 AM with a stated reason of "LULD pause."November 23, 2021 | marketbeat.comTrading was temporarily halted for "CRXT" at 11:11 AM with a stated reason of "LULD pause."November 23, 2021 | marketbeat.comTrading was temporarily halted for "CRXT" at 10:11 AM with a stated reason of "LULD pause."November 23, 2021 | marketbeat.com Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTQ and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] CRXTQ Media Mentions By Week CRXTQ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRXTQ News Sentiment▼0.000.57▲Average Medical News Sentiment CRXTQ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRXTQ Articles This Week▼00▲CRXTQ Articles Average Week Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALVO News AVXT News CRXM News AMGN News GILD News ARGX News NVZMY News BNTX News BIIB News MRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CRXTQ) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarus Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clarus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
